AIM ImmunoTech Announces NYSE American Removal of Trading Suspension
Company expected to resume trading on the NYSE American on Tuesday, June 17, 2025OCALA, Fla., June 12, 2025 (GLOBE NEWSWIRE)...
Clinical Trial
Nectero Medical Secures Category III CPT Codes for Investigational Therapy to Treat Small- to Medium-Sized AAAs
Milestone paves the way for future reimbursement of the Nectero EAST® SystemTEMPE, Az., June 12, 2025 (GLOBE NEWSWIRE) -- Nectero...
AIM ImmunoTech Announces NYSE American Removal of Trading Suspension
Company expected to resume trading on the NYSE American on Tuesday, June 17, 2025OCALA, Fla., June 12, 2025 (GLOBE NEWSWIRE)...
AIM ImmunoTech Announces NYSE American Removal of Trading Suspension
Company expected to resume trading on the NYSE American on Tuesday, June 17, 2025OCALA, Fla., June 12, 2025 (GLOBE NEWSWIRE)...
Nectero Medical Secures Category III CPT Codes for Investigational Therapy to Treat Small- to Medium-Sized AAAs
Milestone paves the way for future reimbursement of the Nectero EAST® SystemTEMPE, Az., June 12, 2025 (GLOBE NEWSWIRE) -- Nectero...
Nectero Medical Secures Category III CPT Codes for Investigational Therapy to Treat Small- to Medium-Sized AAAs
Milestone paves the way for future reimbursement of the Nectero EAST® SystemTEMPE, Az., June 12, 2025 (GLOBE NEWSWIRE) -- Nectero...
Rgenta Therapeutics Presents Preclinical Data from Lead Program, RGT-61159, a Potent and Selective Small Molecule Inhibitor of MYB RNA, Supporting its Application in the Treatment of Acute Myeloid Leukemia (AML)
Data are being presented at the 30th Annual Congress of the European Hematology Association 2025 (EHA2025)WOBURN, Mass., June 12, 2025...
Rgenta Therapeutics Presents Preclinical Data from Lead Program, RGT-61159, a Potent and Selective Small Molecule Inhibitor of MYB RNA, Supporting its Application in the Treatment of Acute Myeloid Leukemia (AML)
Data are being presented at the 30th Annual Congress of the European Hematology Association 2025 (EHA2025)WOBURN, Mass., June 12, 2025...
Rgenta Therapeutics Presents Preclinical Data from Lead Program, RGT-61159, a Potent and Selective Small Molecule Inhibitor of MYB RNA, Supporting its Application in the Treatment of Acute Myeloid Leukemia (AML)
Data are being presented at the 30th Annual Congress of the European Hematology Association 2025 (EHA2025)WOBURN, Mass., June 12, 2025...
Werewolf Therapeutics to Participate in the BIO International Convention
WATERTOWN, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical...
Werewolf Therapeutics to Participate in the BIO International Convention
WATERTOWN, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical...
Third Harmonic Bio Announces Stockholder Approval of Plan of Liquidation and Dissolution, Updated THB335 Phase 1 Clinical Data, and Initiation of Sale of THB335
Stockholders overwhelmingly approved liquidation and dissolution of the Company at the June 5, 2025 Annual Meeting Initial distribution currently expected...
Third Harmonic Bio Announces Stockholder Approval of Plan of Liquidation and Dissolution, Updated THB335 Phase 1 Clinical Data, and Initiation of Sale of THB335
Stockholders overwhelmingly approved liquidation and dissolution of the Company at the June 5, 2025 Annual Meeting Initial distribution currently expected...
Disc Medicine Presents Positive Clinical Data Updates Across Portfolio at the European Hematology Association (EHA) 2025 Annual Congress
Positive updates across all programs, including longer term efficacy and safety data from the HELIOS open-label extension trial of bitopertin...
Disc Medicine Presents Positive Clinical Data Updates Across Portfolio at the European Hematology Association (EHA) 2025 Annual Congress
Positive updates across all programs, including longer term efficacy and safety data from the HELIOS open-label extension trial of bitopertin...
Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress
– Encouraging clinical activity with deep responses demonstrated in the KOMET-007 trial with the combination of 600 mg ziftomenib with...
Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress
– Encouraging clinical activity with deep responses demonstrated in the KOMET-007 trial with the combination of 600 mg ziftomenib with...
Positive PoNSTEP Study Results Presented at Consortium of Multiple Sclerosis Centers Annual Meeting
-PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy® on gait deficit improvement in people...
Positive PoNSTEP Study Results Presented at Consortium of Multiple Sclerosis Centers Annual Meeting
-PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy® on gait deficit improvement in people...
American Journal of Respiratory and Critical Care Medicine Publishes Landmark Data on AeroPace® System’s Breakthrough Results in Ventilator Weaning
International multi-center trial demonstrates AeroPace strengthens the diaphragm by 50%, weans more patients from ventilation, and reduces ventilator time by...